Shanghai Enka Cell Technology

Enka Cell is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of next-generation Natural Killer (NK) cell therapies. Founded by Academician Tian Zhigang, a leading expert in NK cell biology, the company leverages synthetic immunology to create logic-gate controlled and gene-edited NK cells designed to overcome the immunosuppressive tumor microenvironment. Their lead candidate, NK010, is an allogeneic, non-genetically modified NK cell therapy currently in clinical trials for acute myeloid leukemia and ovarian cancer. Enka Cell's proprietary SynNK platform enables the large-scale production of highly potent NK cells from various sources, including peripheral blood and induced pluripotent stem cells. The company aims to provide off-the-shelf, cost-effective cellular immunotherapies for both hematological and solid tumors.